Non-alcoholic Fatty Liver Disease: Diagnosis and Treatment
Authors
Dewa Ayu Vania Novista AnjaniDOI:
10.29303/jbt.v23i3.5016Published:
2023-06-08Issue:
Vol. 23 No. 3 (2023): July - SeptemberKeywords:
diagnosis, liver abnormalities, management, non-alcoholic fatty liver disease (NAFLD).Articles
Downloads
How to Cite
Downloads
Metrics
Abstract
NAFLD is a highly prevalent liver disease that encompasses various clinical presentations. Initially, patients are at high risk of experiencing cardiovascular events, while some may progress to advanced fibrosis or even cirrhosis, thus increasing the risk of liver decompensation and mortality. Accurate methods of diagnosing and managing NAFLD are crucial in order to minimize the impact of the disease. Moreover, the diagnosis of NAFLD is often overlooked by doctors and only receives attention when it leads to serious complications. The purpose of this literature review is to enhance the understanding of Non-alcoholic fatty liver disease, with a focus on discussing the methods of diagnosing and managing NAFLD based on published literature references from various databases. NAFLD can be diagnosed through a comprehensive approach involving clinical laboratory findings, radiological modalities, and biopsy. The management of NAFLD includes lifestyle modifications, pharmacological interventions, and liver transplantation. Despite the availability of various diagnostic methods for NAFLD in this era, biopsy remains the gold standard. The pharmacological treatment options for NAFLD are still limited, and the cornerstone of any treatment is diet, weight loss, and physical exercise. Early diagnosis and a comprehensive management approach can be beneficial for patients with NAFLD.
References
Adams, L.A., Lymp, J.F., st. Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A. and Angulo, P. (2005), “The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study”, Gastroenterology, Vol. 129 No. 1, pp. 113–121. DOI: 10.1053/j.gastro.2005.04.014
Alexander, M., Loomis, A.K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., et al. (2018), “Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease”, BMC Medicine, Vol. 16 No. 1, p. 130. DOI: 10.1186/s12916-018-1103-x.
Bae, J.C., Suh, S., Park, S.E., Rhee, E.J., Park, C.Y., Oh, K.W., Park, S.W., et al. (2012), “Regular Exercise Is Associated with a Reduction in the Risk of NAFLD and Decreased Liver Enzymes in Individuals with NAFLD Independent of Obesity in Korean Adults”, PLoS ONE, Vol. 7 No. 10, p. e46819. DOI: 10.1371/journal.pone.0046819.
Banini, B.A. and Sanyal, A.J. (2016), “Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.”, Clinical Medicine Insights. Therapeutics, Vol. 8, pp. 75–84. DOI: 10.4137/cmt.s18885.
Bayard, M., Holt, J. and Boroughs, E. (2006), “Nonalcoholic fatty liver disease.”, American Family Physician, Vol. 73 No. 11, pp. 1961–8.
Bedossa, P., Burt, A.A., Gouw, A.H.A., Lackner, C., Schirmacher, P., Terracciano, L., Tiniakos, D., et al. (2014), “Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease”, Hepatology (Baltimore, Md.), Hepatology, 60 (2): 565–575. DOI: 10.1002/HEP.27173.
Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., et al. (2006), “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis”, The New England Journal of Medicine, N Engl J Med, Vol. 355 No. 22, pp. 2297–2307. DOI: 10.1056/NEJMOA060326.
Berson, A., de Beco, V., Lettéron, P., Robin, M.A., Moreau, C., Kahwaji, J. el, Verthier, N., et al. (1998), “Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes”, Gastroenterology, Vol. 114 No. 4, pp. 764–774. DOI: 10.1016/S0016-5085(98)70590-6.
Browning, J.D., Baker, J.A., Rogers, T., Davis, J., Satapati, S. and Burgess, S.C. (2011), “Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction”, The American Journal of Clinical Nutrition, Vol. 93 No. 5, pp. 1048–1052. DOI: 10.3945/ajcn.110.007674.
Browning, J.D., Weis, B., Davis, J., Satapati, S., Merritt, M., Malloy, C.R. and Burgess, S.C. (2008), “Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restriction”, Hepatology, Vol. 48 No. 5, pp. 1487–1496, DOI: 10.1002/hep.22504.
Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016), “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)”, Metabolism, Vol. 65 No. 8, pp. 1038–1048. DOI: 10.1016/j.metabol.2015.12.012.
Byrne, C.D. and Targher, G. (2015), “NAFLD: A multisystem disease”, Journal of Hepatology, Vol. 62 No. 1, pp. S47–S64. DOI: 10.1016/j.jhep.2014.12.012.
Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., Harrison, S.A., et al. (2018), “The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”, Hepatology (Baltimore, Md.), Hepatology, 67 (1): 328–357. DOI: 10.1002/HEP.29367.
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., et al. (2012), “The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association”, Hepatology, Vol. 55 No. 6, pp. 2005–2023. DOI: 10.1002/hep.25762.
Charatcharoenwitthaya, P., Lindor, K.D. and Angulo, P. (2012), “The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease”, Digestive Diseases and Sciences, Vol. 57 No. 7, pp. 1925–1931. DOI: 10.1007/s10620-012-2098-3.
Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K. and Dierkhising, R.A. (2011), “Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States”, Gastroenterology, Gastroenterology, 141 (4); 1249–1253. DOI: 10.1053/J.GASTRO.2011.06.061.
Chitturi, S., Wong, V.W.S., Chan, W.K., Wong, G.L.H., Wong, S.K.H., Sollano, J., Ni, Y.H., et al. (2018), “The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups”, Journal of Gastroenterology and Hepatology, J Gastroenterol Hepatol, 33(1); 86–98. DOI: 10.1111/JGH.13856.
Choudhury, J. and Sanyal, A.J. (2004), “Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease”, Clinics in Liver Disease, Clin Liver Dis, 8(3); 575–594. DOI: 10.1016/j.cld.2004.04.006.
Day, C.P. and James, O.F.W. (1998), “Steatohepatitis: A tale of two ‘hits’?”, Gastroenterology, 114 (4): 842–845. DOI: 10.1016/S0016-5085(98)70599-2.
Ekstedt, M., Franzén, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G. and Kechagias, S. (2006), “Long-term follow-up of patients with NAFLD and elevated liver enzymes”, Hepatology, 44 (4): 865–873. DOI: 10.1002/hep.21327.
Enjoji. (2009), “Impact of cholesterol metabolism and the LXRα-SREBP-1c pathway on nonalcoholic fatty liver disease”, International Journal of Molecular Medicine, 23 (5). DOI: 10.3892/ijmm_00000170.
Estes, C., Razavi, H., Loomba, R., Younossi, Z. and Sanyal, A.J. (2018), “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.”, Hepatology (Baltimore, Md.), 67 (1): 123–133. DOI: 10.1002/hep.29466.
Fan, J.-G. (2013), “Epidemiology of alcoholic and nonalcoholic fatty liver disease in China.”, Journal of Gastroenterology and Hepatology, Vol. 28 Suppl 1, pp. 11–7. DOI: 10.1111/jgh.12036.
Fan, J.-G., Kim, S.-U. and Wong, V.W.-S. (2017), “New trends on obesity and NAFLD in Asia.”, Journal of Hepatology, 67 (4); 862–873. DOI: 10.1016/j.jhep.2017.06.003.
Farrell, G.C. and Larter, C.Z. (2006), “Nonalcoholic fatty liver disease: From steatosis to cirrhosis”, Hepatology, Vol. 43 No. S1, pp. S99–S112. DOI: 10.1002/hep.20973.
Flora, K., Hahn, M., Rosen, H. and Benner, K. (1998), “Milk thistle (Silybum marianum) for the therapy of liver disease”, The American Journal of Gastroenterology, Am J Gastroenterol, Vol. 93 No. 2, pp. 139–143. DOI: 10.1111/J.1572-0241.1998.00139.X.
Hakeem, A.R., Cockbain, A.J., Raza, S.S., Pollard, S.G., Toogood, G.J., Attia, M.A., Ahmad, N., et al. (2013), “Increased morbidity in overweight and obese liver transplant recipients: A single-center experience of 1325 patients from the United Kingdom”, Liver Transplantation, EurekaMag, 19(5): 551–562. DOI: 10.1002/lt.23618.
Johnson, N.A., Sachinwalla, T., Walton, D.W., Smith, K., Armstrong, A., Thompson, M.W. and George, J. (2009), “Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss”, Hepatology, 50(4): 1105–1112. DOI: 10.1002/hep.23129.
Lall, C.G., Aisen, A.M., Bansal, N. and Sandrasegaran, K. (2008), “Nonalcoholic Fatty Liver Disease”, American Journal of Roentgenology, 190 (4): 993–1002. DOI: 10.2214/AJR.07.2052.
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., et al. (2015), “Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients”, Gastroenterology, 149(2): 379–388. DOI: 10.1053/j.gastro.2015.04.014.
Lavine, J.E., Schwimmer, J.B., van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., Abrams, S.H., et al. (2011), “Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial”, JAMA, JAMA, Vol. 305 No. 16, pp. 1659–1668, doi: 10.1001/JAMA.2011.520.
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S. and Bolondi, L. (2018), “Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis”, World Journal of Gastroenterology, Vol. 24 No. 30, pp. 3361–3373, doi: 10.3748/wjg.v24.i30.3361.
Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., Fujii, H., et al. (2019), “Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.”, The Lancet. Gastroenterology & Hepatology, Vol. 4 No. 5, pp. 389–398, doi: 10.1016/S2468-1253(19)30039-1.
Liu, J., Wang, G., Jia, Y. and Xu, Y. (2015), “GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease”, Diabetes/Metabolism Research and Reviews, Vol. 31 No. 4, pp. 329–335, doi: 10.1002/dmrr.2580.
Mahady, S.E., Webster, A.C., Walker, S., Sanyal, A. and George, J. (2011), “The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis”, Journal of Hepatology, J Hepatol, Vol. 55 No. 6, pp. 1383–1390, doi: 10.1016/J.JHEP.2011.03.016.
Marchesini, G., Day, C.P., Dufour, J.F., Canbay, A., Nobili, V., Ratziu, V., Tilg, H., et al. (2016), “EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease”, Journal of Hepatology, J Hepatol, Vol. 64 No. 6, pp. 1388–1402, doi: 10.1016/J.JHEP.2015.11.004.
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., Pigeyre, M., et al. (2009), “Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease”, Gastroenterology, Gastroenterology, Vol. 137 No. 2, pp. 532–540, doi: 10.1053/J.GASTRO.2009.04.052.
McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P. and Anstee, Q.M. (2015), “Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management”, Journal of Hepatology, J Hepatol, Vol. 62 No. 5, pp. 1148–1155, doi: 10.1016/J.JHEP.2014.11.034.
Mofrad, P. (2003), “Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values”, Hepatology, Vol. 37 No. 6, pp. 1286–1292, doi: 10.1053/jhep.2003.50229.
Nagra, N., Penna, R., La Selva, D., Coy, D., Siddique, A. and Burman, B. (2021), “Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis.”, Journal of Clinical and Translational Research, Vol. 7 No. 5, pp. 641–647.
Nair, S., Verma, S. and Thuluvath, P.J. (2002), “Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States”, Hepatology, Hepatology, Vol. 35 No. 1, pp. 105–109, doi: 10.1053/jhep.2002.30318.
National Institute for Health and Care Excellence. (2016), Non-Alcoholic Fatty Liver Disease Assessment and Management, National Institute for Health and Care Excellence (NICE), London.
Nd, A.M. (2019), “Non-Alcoholic Fatty Liver Disease, an Overview.”, Integrative Medicine (Encinitas, Calif.), Vol. 18 No. 2, pp. 42–49.
Nielsen, E.M., Anderson, K.P., Marsden, J., Zhang, J. and Schreiner, A.D. (2022), “Nonalcoholic Fatty Liver Disease Underdiagnosis in Primary Care: What Are We Missing?”, Journal of General Internal Medicine, Vol. 37 No. 10, pp. 2587–2590, doi: 10.1007/s11606-021-07197-3.
Niikura, T., Imajo, K., Ozaki, A., Kobayashi, T., Iwaki, M., Honda, Y., Kessoku, T., et al. (2020), “Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver”, Diagnostics, MDPI AG, Vol. 10 No. 3, p. 129, doi: 10.3390/diagnostics10030129.
Oarada, M., Takahashi-Nakaguchi, A., Abe, T., Nikawa, T., Miki, T. and Gonoi, T. (2015), “Refeeding with glucose rather than fructose elicits greater hepatic inflammatory gene expression in mice”, Nutrition, Vol. 31 No. 5, pp. 757–765, doi: 10.1016/j.nut.2014.11.014.
Pafili, K. and Roden, M. (2021), “Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans”, Molecular Metabolism, Vol. 50, p. 101122, doi: 10.1016/j.molmet.2020.101122.
Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T. and Ratziu, V. (2013), “A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver”, Journal of Hepatology, J Hepatol, Vol. 59 No. 3, pp. 550–556, doi: 10.1016/J.JHEP.2013.04.027.
Promrat, K., Kleiner, D.E., Niemeier, H.M., Jackvony, E., Kearns, M., Wands, J.R., Fava, J.L., et al. (2010), “Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis”, Hepatology, Vol. 51 No. 1, pp. 121–129, doi: 10.1002/hep.23276.
Rinella, M.E. and Sanyal, A.J. (2016), “Management of NAFLD: a stage-based approach”, Nature Reviews Gastroenterology & Hepatology, Vol. 13 No. 4, pp. 196–205, doi: 10.1038/nrgastro.2016.3.
Sanyal, A.J. (2002), “AGA technical review on nonalcoholic fatty liver disease”, Gastroenterology, Vol. 123 No. 5, pp. 1705–1725, doi: 10.1053/gast.2002.36572.
Sanyal, A.J., Chalasani, N., Kowdley, K. v., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., et al. (2010a), “Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis”, New England Journal of Medicine, Massachusetts Medical Society, Vol. 362 No. 18, pp. 1675–1685, doi: 10.1056/NEJMOA0907929/SUPPL_FILE/NEJMOA0907929_DISCLOSURES.PDF.
Sanyal, A.J., Chalasani, N., Kowdley, K. v., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., et al. (2010b), “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis”, The New England Journal of Medicine, N Engl J Med, Vol. 362 No. 18, pp. 1675–1685, doi: 10.1056/NEJMOA0907929.
Sanyal, A.J., Mofrad, P.S., Contos, M.J., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., et al. (2004), “A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis”, Clinical Gastroenterology and Hepatology, Clin Gastroenterol Hepatol, Vol. 2 No. 12, pp. 1107–1115, doi: 10.1016/S1542-3565(04)00457-4.
Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Brethauer, S.A., Navaneethan, S.D., Aminian, A., et al. (2014), “Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes”, The New England Journal of Medicine, N Engl J Med, Vol. 370 No. 21, pp. 2002–2013, doi: 10.1056/NEJMOA1401329.
Seto, W.-K. and Yuen, M.-F. (2017), “Nonalcoholic fatty liver disease in Asia: emerging perspectives.”, Journal of Gastroenterology, Vol. 52 No. 2, pp. 164–174, doi: 10.1007/s00535-016-1264-3.
Seyda Seydel, G., Kucukoglu, O., Altinbasv, A., Demir, O.O., Yilmaz, S., Akkiz, H., Otan, E., et al. (2016), “ Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries.”, Annals of Hepatology, Vol. 15 No. 5, pp. 662–72, doi: 10.5604/16652681.1212316.
Shim, J.-J. (2012), “Body iron, serum ferritin, and nonalcoholic fatty liver disease”, The Korean Journal of Hepatology, Vol. 18 No. 1, p. 105, doi: 10.3350/kjhep.2012.18.1.105.
Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H. and Loomba, R. (2015), “Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies”, Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, Clin Gastroenterol Hepatol, Vol. 13 No. 4, pp. 643-654.e9, doi: 10.1016/J.CGH.2014.04.014.
Slentz, C.A., Bateman, L.A., Willis, L.H., Shields, A.T., Tanner, C.J., Piner, L.W., Hawk, V.H., et al. (2011), “Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT”, American Journal of Physiology-Endocrinology and Metabolism, Vol. 301 No. 5, pp. E1033–E1039, doi: 10.1152/ajpendo.00291.2011.
Sweet, P.H., Khoo, T. and Nguyen, S. (2017), “Nonalcoholic Fatty Liver Disease”, Primary Care: Clinics in Office Practice, Vol. 44 No. 4, pp. 599–607, doi: 10.1016/j.pop.2017.07.003.
Tandon, P., Ney, M., Irwin, I., Ma, M.M., Gramlich, L., Bain, V.G., Esfandiari, N., et al. (2012), “Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value”, Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Liver Transpl, Vol. 18 No. 10, pp. 1209–1216, doi: 10.1002/LT.23495.
Traber, P.G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.I. and Friedman, S.L. (2013), “Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease”, PloS One, PLoS One, Vol. 8 No. 10, doi: 10.1371/JOURNAL.PONE.0075361.
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S.L., et al. (2015), “Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis”, Gastroenterology, Vol. 149 No. 2, pp. 367-378.e5, doi: 10.1053/j.gastro.2015.04.005.
Wah Kheong, C., Nik Mustapha, N.R. and Mahadeva, S. (2017), “A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis”, Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, Clin Gastroenterol Hepatol, Vol. 15 No. 12, pp. 1940-1949.e8, doi: 10.1016/J.CGH.2017.04.016.
Wong, S.-W. and Chan, W.-K. (2020), “Epidemiology of non-alcoholic fatty liver disease in Asia”, Indian Journal of Gastroenterology, Vol. 39 No. 1, pp. 1–8, doi: 10.1007/s12664-020-01018-x.
Wong, V.W.-S., Chan, R.S.-M., Wong, G.L.-H., Cheung, B.H.-K., Chu, W.C.-W., Yeung, D.K.-W., Chim, A.M.-L., et al. (2013), “Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial”, Journal of Hepatology, Vol. 59 No. 3, pp. 536–542, doi: 10.1016/j.jhep.2013.04.013.
Yasutake, K., Nakamuta, M., Shima, Y., Ohyama, A., Masuda, K., Haruta, N., Fujino, T., et al. (2009), “Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol”, Scandinavian Journal of Gastroenterology, Vol. 44 No. 4, pp. 471–477, doi: 10.1080/00365520802588133.
Zhai, H.-L., Wang, N.-J., Han, B., Li, Q., Chen, Y., Zhu, C.-F., Chen, Y.-C., et al. (2016), “Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China))”, British Journal of Nutrition, Vol. 115 No. 8, pp. 1352–1359, doi: 10.1017/S0007114516000386.
Zhang, J.-Z., Cai, J.-J., Yu, Y., She, Z.-G. and Li, H. (2019), “Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.”, Gene Expression, Vol. 19 No. 3, pp. 187–198, doi: 10.3727/105221619X15553433838609.
License
Copyright (c) 2023 Dewa Ayu Vania Novista Anjani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
